The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
Inclusion in Russell Indexes: The Oncology Institute, Inc. (TOI) will be added to the Russell 2000® and Russell 3000® indexes after the annual reconstitution on June 27, 2025, marking a significant milestone in the company's growth journey.
Impact of Inclusion: TOI's CEO highlighted that this inclusion reflects their innovative, value-based approach to cancer care and aims to improve patient outcomes while creating long-term shareholder value.
Trade with 70% Backtested Accuracy
Analyst Views on TOIIW
No data
About the author
The Oncology Institute to Join the Noble Capital Markets Virtual Equity Conference for Emerging Growth
Conference Participation: The Oncology Institute's CEO Dr. Daniel Virnich and CFO Rob Carter will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025, at 11:00am ET.
Company Overview: Founded in 2007, The Oncology Institute specializes in value-based community oncology care, serving approximately 1.9 million patients with over 180 clinicians and more than 100 clinics across five states.
The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
Inclusion in Russell Indexes: The Oncology Institute, Inc. (TOI) will be added to the Russell 2000® and Russell 3000® indexes after the annual reconstitution on June 27, 2025, marking a significant milestone in the company's growth journey.
Impact of Inclusion: TOI's CEO highlighted that this inclusion reflects their innovative, value-based approach to cancer care and aims to improve patient outcomes while creating long-term shareholder value.
The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer
New Appointment: Dr. Jeffrey Langsam has been appointed as the Chief Clinical Officer of The Oncology Institute, effective May 13, 2025, bringing extensive experience from Cigna Healthcare and Aetna to enhance therapeutic decision-making and clinical engagement.
Organizational Growth: The Oncology Institute aims to expand its value-based oncology services and MSO model under Dr. Langsam's leadership, focusing on improving patient care and strengthening partnerships in a rapidly evolving healthcare landscape.
The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference
Conference Participation: The Oncology Institute, Inc. will have CEO Dr. Daniel Virnich and CFO Rob Carter attending B. Riley's 25th Annual Institutional Investor Conference on May 21, 2025, in Marina Del Rey, CA.
About The Oncology Institute: Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients with advanced services through a network of more than 70 clinics and 120 clinicians.
The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates
TOI's Presentation at ASCO Annual Meeting: The Oncology Institute, Inc. has been selected to present an abstract at the ASCO Annual Meeting, showcasing data that highlights significant cost savings and reduced hospitalizations linked to its High-Value Cancer Care model.
Clinical Outcomes of TOI's HVCC Model: The study reports a 53% reduction in Emergency Department use, a 68% decrease in hospitalizations, and a $12,000 lower total cost of care per patient, while maintaining high clinical outcomes for oncology patients.
The Oncology Institute of Hope and Innovation Expands Research Partnership with Helios Clinical Across Markets, Enhancing Access to Cutting-Edge Cancer Trials
Expansion of Partnership: The Oncology Institute, Inc. (TOI) is expanding its partnership with Helios Clinical Research to enhance clinical research integration in community oncology, building on a successful collaboration in Florida.
Strategic Benefits: This partnership aims to improve patient access to clinical trials, streamline trial performance for sponsors, and promote health equity by enrolling diverse patient populations in oncology research.
The Oncology Institute to Join the Noble Capital Markets Virtual Equity Conference for Emerging Growth
Conference Participation: The Oncology Institute's CEO Dr. Daniel Virnich and CFO Rob Carter will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025, at 11:00am ET.
Company Overview: Founded in 2007, The Oncology Institute specializes in value-based community oncology care, serving approximately 1.9 million patients with over 180 clinicians and more than 100 clinics across five states.
The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
Inclusion in Russell Indexes: The Oncology Institute, Inc. (TOI) will be added to the Russell 2000® and Russell 3000® indexes after the annual reconstitution on June 27, 2025, marking a significant milestone in the company's growth journey.
Impact of Inclusion: TOI's CEO highlighted that this inclusion reflects their innovative, value-based approach to cancer care and aims to improve patient outcomes while creating long-term shareholder value.
The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer
New Appointment: Dr. Jeffrey Langsam has been appointed as the Chief Clinical Officer of The Oncology Institute, effective May 13, 2025, bringing extensive experience from Cigna Healthcare and Aetna to enhance therapeutic decision-making and clinical engagement.
Organizational Growth: The Oncology Institute aims to expand its value-based oncology services and MSO model under Dr. Langsam's leadership, focusing on improving patient care and strengthening partnerships in a rapidly evolving healthcare landscape.
The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference
Conference Participation: The Oncology Institute, Inc. will have CEO Dr. Daniel Virnich and CFO Rob Carter attending B. Riley's 25th Annual Institutional Investor Conference on May 21, 2025, in Marina Del Rey, CA.
About The Oncology Institute: Founded in 2007, TOI specializes in value-based cancer care, serving over 1.8 million patients with advanced services through a network of more than 70 clinics and 120 clinicians.
The Oncology Institute to Present at Upcoming ASCO Annual Meeting on High-Value Cancer Care Model Outcomes Showing Cost Savings and Lower Hospitalization Rates
TOI's Presentation at ASCO Annual Meeting: The Oncology Institute, Inc. has been selected to present an abstract at the ASCO Annual Meeting, showcasing data that highlights significant cost savings and reduced hospitalizations linked to its High-Value Cancer Care model.
Clinical Outcomes of TOI's HVCC Model: The study reports a 53% reduction in Emergency Department use, a 68% decrease in hospitalizations, and a $12,000 lower total cost of care per patient, while maintaining high clinical outcomes for oncology patients.
The Oncology Institute of Hope and Innovation Expands Research Partnership with Helios Clinical Across Markets, Enhancing Access to Cutting-Edge Cancer Trials
Expansion of Partnership: The Oncology Institute, Inc. (TOI) is expanding its partnership with Helios Clinical Research to enhance clinical research integration in community oncology, building on a successful collaboration in Florida.
Strategic Benefits: This partnership aims to improve patient access to clinical trials, streamline trial performance for sponsors, and promote health equity by enrolling diverse patient populations in oncology research.
